{"title":"Correction to “Treatment-Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet-Rich Plasma in Bladder Pain Syndrome”","authors":"","doi":"10.1111/luts.70070","DOIUrl":"10.1111/luts.70070","url":null,"abstract":"<p>W. R. Yu, T. C. Hsieh, Y. H. Wu, and H. C. Kuo, “Treatment-Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet-Rich Plasma in Bladder Pain Syndrome,” <i>Lower Urinary Tract Symptoms</i> 18, no.2 (March 2026): e70057, https://doi.org/10.1111/luts.70057.</p><p>The Institutional Review Board approval number was incorrectly stated as “IRB113-015-B” instead of “IRB115-015-B” in subsection 2.1 and in the Ethics Statement section.</p><p>Accordingly, the first sentence of the third paragraph in subsection 2.1 should read: “The study protocol was approved by the Research Ethics Committee of Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (IRB115-015-B).”</p><p>The Ethics Statement section should read:</p><p>Ethics Statement</p><p>The Research Ethics Committee of the Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, approved this study (IRB115-015-B).</p><p>We apologize for this error.</p>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Keisuke Ishikawa, Akira Tsujimura, Riho Kasai, Yukiko Ota, Takashi Kanda, Yuta Anno, Haruhiko Wakita, Ayumu Taniguchi, Yuka Uesaka, Taiji Nozaki, Masato Shirai, Shigeo Horie
{"title":"In Older Men With Persistent Nocturia Due to Nocturnal Polyuria, Desmopressin Is Effective for Those With Higher Muscle Mass.","authors":"Keisuke Ishikawa, Akira Tsujimura, Riho Kasai, Yukiko Ota, Takashi Kanda, Yuta Anno, Haruhiko Wakita, Ayumu Taniguchi, Yuka Uesaka, Taiji Nozaki, Masato Shirai, Shigeo Horie","doi":"10.1111/luts.70063","DOIUrl":"10.1111/luts.70063","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the efficacy of desmopressin in older men with persistent nocturia due to nocturnal polyuria and then determine the independent factors affecting the efficacy of desmopressin.</p><p><strong>Methods: </strong>Desmopressin 50 mg was administered for 12 weeks to 49 patients (76.3 ± 7.3 years) with persistent nocturia. Physical factors including prostate volume, muscle mass, basal metabolic rate, maximum flow rate, voiding diary, serum sodium, and scores of several questionnaires were evaluated. First, we evaluated the efficacy of desmopressin and then investigated the independent factors influencing its efficacy.</p><p><strong>Results: </strong>Nocturnal urinary frequency decreased significantly from 3.9 ± 1.0 to 1.9 ± 1.1 times/night. The nocturnal urine volume and nocturnal polyuria index significantly decreased from 761.6 ± 273.8 to 445.5 ± 159.3 mL and from 45.5% ± 10.2% to 32.3% ± 14.4% respectively. The total International Prostate Symptom Score improved significantly, as did the Quality of Life index. However, the Overactive Bladder Symptom Score and the Athens Insomnia Scale did not show significant improvement. Only muscle mass at the baseline measurement was identified as a factor predictive of affecting the efficacy of desmopressin based on the decrease in nocturnal urinary frequency.</p><p><strong>Conclusions: </strong>This study is the first, to our knowledge, to determine the independent factors affecting the efficacy of desmopressin.</p>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":"e70063"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply to: \"Letter to the Editor: Association Between Frailty and Short-Term Treatment-Related Adverse Events in Patients With Overactive Bladder\".","authors":"Sohei Iwagami","doi":"10.1111/luts.70065","DOIUrl":"https://doi.org/10.1111/luts.70065","url":null,"abstract":"","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":"e70065"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maximilian Filzmayer, Miriam I Traumann, Clara Humke, Matthias J Müller, Philipp C Mandel, Luis A Kluth, Andreas Becker, Felix K-H Chun, Marina Kosiba
{"title":"Rates and Predictors of Persistent LUTS Medication Use After Laser Enucleation of the Prostate.","authors":"Maximilian Filzmayer, Miriam I Traumann, Clara Humke, Matthias J Müller, Philipp C Mandel, Luis A Kluth, Andreas Becker, Felix K-H Chun, Marina Kosiba","doi":"10.1111/luts.70062","DOIUrl":"10.1111/luts.70062","url":null,"abstract":"<p><strong>Objectives: </strong>To assess rates of medication use for lower urinary tract symptoms (LUTS) over time following laser enucleation of the prostate (LEP) and to identify preoperative predictors of persistent use.</p><p><strong>Methods: </strong>We retrospectively analyzed 864 LEP patients from an institutional tertiary-care database (11/2017-05/2023) with available 24-month follow-up on medication use. Patient-reported use of five drug classes (alpha-blockers, 5-alpha-reductase (AR)-inhibitors, anticholinergics, beta-3-agonists, and phosphodiesterase (PDE)-5-inhibitors) was recorded preoperatively and at one, three, 12, and 24 months after the procedure. Univariable and multivariable logistic regression models were fitted to identify predictors of persistent LUTS medication use.</p><p><strong>Results: </strong>Preoperatively, 84.9% of patients used LUTS medication, decreasing to 12.6% within 24 months of follow-up. Alphablocker (80.9%) and 5-AR-inhibitor (13.8%) use declined to 1.8% and 0%, respectively. Anticholinergic (4.6%) and beta-3-agonist (0.3%) use showed a transient postoperative increase with peaks of 10.9% and 1.0% at 3 months, followed by a decline to 2.7% and 0.4% at 24 months, respectively. PDE-5-inhibitor use (1.8%) increased steadily to 5.4% at 24 months. Patient with persistent use exhibited worse baseline QoL and ICIQ-SF scores and higher rates of adiposity, diabetes mellitus, and ASA score III/IV. In multivariable analysis, only preoperative PDE-5-inhibitor use (adjusted OR 3.26, p = 0.002) and ASA score III/IV (adjusted OR 2.08, p = 0.016) remained independently associated with persistent LUTS medication use.</p><p><strong>Conclusion: </strong>LUTS medication use decreased substantially after LEP, with only a small subset requiring continued medication at 24 months. Preoperative PDE-5-inhibitor use and higher comorbidity burden emerged as independent predictors of persistent LUTS medication use. These findings can refine preoperative counseling regarding postoperative LUTS medication dependence.</p>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":"e70062"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13103631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sung Jin Kim, Sung Gon Park, Sahyun Pak, Ohseong Kwon, Young Goo Lee, Sung Tae Cho
{"title":"Association Between Prior Inguinal Hernia Repair and Early Continence Recovery After Robot-Assisted Radical Prostatectomy.","authors":"Sung Jin Kim, Sung Gon Park, Sahyun Pak, Ohseong Kwon, Young Goo Lee, Sung Tae Cho","doi":"10.1111/luts.70069","DOIUrl":"10.1111/luts.70069","url":null,"abstract":"<p><strong>Objective: </strong>Early post-prostatectomy incontinence (PPI) remains a common concern after robot-assisted radical prostatectomy (RARP). Recovery patterns vary among individuals, and identifying patients at risk of delayed recovery is clinically important. We evaluated whether prior adult inguinal hernia (IH) repair is associated with early continence outcomes after RARP.</p><p><strong>Methods: </strong>We retrospectively analyzed 305 consecutive patients who underwent RARP between 2021 and 2024. Continence was defined as pad-free status, and PPI as use of > 1 pad/day. Continence was assessed at 1 week and at 1, 3, and 6 months postoperatively. Multivariable logistic regression and generalized estimating equation (GEE) modeling were used to evaluate associations, adjusting for age and BMI. Kaplan-Meier and interval-censored Cox models were applied to assess time to continence.</p><p><strong>Results: </strong>Twenty-seven patients (8.9%) had prior IH repair. These patients demonstrated significantly higher rates of PPI at all assessed time points. After adjustment for age and BMI, prior IH repair remained significantly associated with PPI (adjusted ORs 2.99-5.84, all p < 0.05). Longitudinal GEE analysis also suggested a slower recovery pattern in the IH group (adjusted OR 4.05, 95% CI 1.62-10.11, p = 0.003). Kaplan-Meier analysis demonstrated delayed return to continence (log-rank p < 0.001), and interval-censored Cox regression confirmed a significantly lower probability of continence recovery in this group (p = 0.001).</p><p><strong>Conclusions: </strong>Prior IH repair was associated with delayed early continence recovery within 6 months after RARP. Given the limited IH sample and follow-up duration, these findings should be interpreted cautiously as exploratory and hypothesis-generating. Larger prospective studies with longer follow-up are warranted.</p>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":"e70069"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147982003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}